Read More

Novo Nordisk’s Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China

Novo Nordisk warns of Ozempic starter kit scarcity in Germany amid ongoing supply challenges in Europe. Restrictions on off-label use emphasized, with intermittent shortages expected in 2024. Biosimilar Jiyoutai awaits approval in China. FDA tightens Mounjaro supply due to high demand.

LLY

Read More

Newly Listed Lenz Therapeutics’ Vision Loss Experimental Drug Meets Primary Goal In Late-Stage Study

LENZ Therapeutics unveils Phase 3 CLARITY study results on aceclidine formulations, LNZ100 & LNZ101. LNZ100 demonstrates significant improvement in Presbyopia, achieving primary and key secondary endpoints without compromising distance visual acuity. LNZ100's safety profile remains favorable, paving the way for its lead candidacy, poised for mid-2024 NDA submission.

LENZ

Read More

FibroGen Unveils Early Data From Prostate Cancer Candidate, Analyst Advocates Further Exploration In The Landscape

FibroGen reveals Phase 1 results for FG-3246 for metastatic castration-resistant prostate cancer. Promising efficacy metrics and plans for enhanced therapeutic strategies signal potential advancements in treatment. Learn more about this groundbreaking development."

ABBV

Read More

Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand

Citi Research raises price target for Eli Lilly, citing improved risk-adjusted sales outlook for GLP-1 agonist orforglipron. With Phase 3 trials ongoing since 2023, concerns about liver toxicity diminish. Analysts foresee potential sales surpassing $85 billion, closely watching competitive landscape.

LLY